| scholarly article | Q13442814 |
| P50 | author | Marta Crespo | Q64630450 |
| Winfred W Williams | Q106399791 | ||
| P2093 | author name string | D Fitzpatrick | |
| M Pascual | |||
| A B Cosimi | |||
| N Tolkoff-Rubin | |||
| R B Colvin | |||
| S L Saidman | |||
| F L Delmonico | |||
| S Mauiyyedi | |||
| A B Collins | |||
| M L Farrell | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | serology | Q502159 |
| P304 | page(s) | 652-658 | |
| P577 | publication date | 2001-03-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics | |
| P478 | volume | 71 |
| Q38228333 | A Systematic Review and Meta-Analysis of Rituximab in Antibody-mediated Renal Allograft Rejection |
| Q44237301 | A case of acute antidonor antibody-mediated humoral rejection after renal transplantation with specific consideration of serial graft biopsy histology |
| Q46545928 | A case of acute humoral rejection with various depositions of C4d, IgG, IgM, and C3c in peritubular capillaries and/or glomerular capillaries |
| Q73566752 | A case report of a renal transplant recipient developing chronic glomerular rejection with a weak antibody against anti-donor T-cell, only detected by flow-cytometry crossmatch |
| Q44591448 | A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients1 |
| Q38211716 | A systematic review of the role of C4d in the diagnosis of acute antibody-mediated rejection |
| Q39130806 | A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection. |
| Q92311964 | A urinary Common Rejection Module (uCRM) score for non-invasive kidney transplant monitoring |
| Q35890887 | ASSOCIATION BETWEEN DE NOVO DONOR SPECIFIC HLA ANTIBODY, C4D STAINING IN RENAL GRAFT BIOPSY AND GRAFT OUTCOME: A SINGLE CENTER EXPERIENCE |
| Q46208009 | Absence of C4d urinary excretion in the early post-transplant period is associated with improved long-term kidney graft survival |
| Q39826008 | Acute Antibody-Mediated Rejection in Kidney Transplant Based on the 2013 Banff Criteria: Single-Center Experience in Uruguay |
| Q35646152 | Acute Antibody-Mediated Rejection in Presence of MICA-DSA and Successful Renal Re-Transplant with Negative-MICA Virtual Crossmatch |
| Q50583761 | Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy |
| Q37686066 | Advances in immunosuppression for renal transplantation. |
| Q33344697 | An approach to evidence-based therapeutic apheresis |
| Q36778212 | An experimental model of acute humoral rejection of renal allografts associated with concomitant cellular rejection |
| Q47986958 | Analysis of different staining techniques for c4d detection in renal allograft biopsies |
| Q37218092 | Anti-major histocompatibility complex class I-related chain A antibodies in organ transplantation |
| Q47869308 | Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection |
| Q36808030 | Antibody-mediated rejection following renal transplantation |
| Q35915453 | Antibody-mediated rejection in kidney transplantation: a review |
| Q38206175 | Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options |
| Q36131185 | Antibody-mediated rejection of single class I MHC-disparate cardiac allografts |
| Q36666906 | Antibody-mediated rejection of the kidney after simultaneous pancreas-kidney transplantation |
| Q37332696 | Antibody-mediated rejection: treatment alternatives and outcomes. |
| Q33804303 | Assessment of Circulating Protein Signatures for Kidney Transplantation in Pediatric Recipients |
| Q73810384 | Association of humoral immunity and bronchiolitis obliterans syndrome |
| Q36429791 | B cells: a rational target in alloantibody-mediated solid organ transplantation rejection |
| Q37263143 | C1Q Assay Results in Complement-Dependent Cytotoxicity Crossmatch Negative Renal Transplant Candidates with Donor-Specific Antibodies: High Specificity but Low Sensitivity When Predicting Flow Crossmatch |
| Q38430795 | C4d immunoreactivity of intraoperative zero-hour biopsy in renal allograft |
| Q52934767 | C4d in acute rejection after liver transplantation--a valuable tool in differential diagnosis to hepatitis C recurrence. |
| Q44461489 | Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. |
| Q36379451 | Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation |
| Q51058705 | Circulating NK-cell subsets in renal allograft recipients with anti-HLA donor-specific antibodies. |
| Q38163419 | Clinical efficacy of rituximab for acute rejection in kidney transplantation: a meta-analysis |
| Q38079301 | Clinical relevance of antibody development in renal transplantation |
| Q47880758 | Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? |
| Q43483642 | Combined therapy of deoxyspergualin and plasmapheresis: a useful treatment for antibody-mediated acute rejection after kidney transplantation |
| Q33648605 | Compartmental localization and clinical relevance of MICA antibodies after renal transplantation |
| Q35142594 | Complement C4d in graft capillaries -- the missing link in the recognition of humoral alloreactivity |
| Q44419254 | Complement activation in early protocol kidney graft biopsies after living-donor transplantation1 |
| Q39718995 | Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates |
| Q51744862 | Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies. |
| Q36204503 | De Novo Donor-Specific HLA Antibody Development and Peripheral CD4(+)CD25(high) Cells in Kidney Transplant Recipients: A Place for Interaction? |
| Q53570974 | Detection and analysis of HLA class I and class II specific alloantibodies in the sera of dialysis recipients waiting for a renal retransplantation. |
| Q84871050 | Detection of plasma cells, C4d deposits and donor-specific antibodies on sequential graft biopsies of renal transplant recipients with chronic dysfunction |
| Q53918403 | Diagnosis and treatment of acute humoral rejection after kidney transplantation: preliminary experience. |
| Q35554487 | Diagnosis and treatment of antibody-mediated kidney allograft rejection |
| Q62658655 | Diagnostic Value of C4d in Renal Allograft Biopsies in Different Clinical Settings: Absence of C4d in Grafts From Non-Heart-Beating Donors |
| Q37308415 | Differential effects of donor-specific alloantibody |
| Q42997805 | ELISA-based detection of C4d after liver transplantation--a helpful tool for differential diagnosis between acute rejection and HCV-recurrence? |
| Q46245989 | Early and late humoral rejection: a clinicopathologic entity in two times |
| Q35583498 | Effector mechanisms in transplant rejection |
| Q37541912 | Eicosapentenoic Acid Attenuates Allograft Rejection in an HLA-B27/EGFP Transgenic Rat Cardiac Transplantation Model |
| Q37960177 | Emerging drugs for the treatment of transplant rejection |
| Q79083547 | Evidence That Humoral Allograft Rejection in Lung Transplant Patients Is Not Histocompatibility Antigen-Related |
| Q74407761 | Fibrosis and atrophy in the renal allograft: interim report and new directions |
| Q37315152 | Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival |
| Q53641782 | Focal peritubular capillary C4d deposition in acute rejection. |
| Q37485481 | Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys |
| Q30276550 | Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue |
| Q34122035 | Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis |
| Q79150257 | HLA-A, B, C, DRB1, DQB1 matching heterogeneity in ‘favourably matched’ kidney recipients |
| Q43906723 | High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis |
| Q35848716 | Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients |
| Q36280431 | Humoral rejection of organ allografts |
| Q35142603 | Humoral theory of transplantation |
| Q36028067 | Impact of pretransplant rituximab induction on highly sensitized kidney recipients: comparison with non-rituximab group. |
| Q51699103 | Impact of the Banff 2013 classification on the diagnosis of suspicious versus conclusive late antibody-mediated rejection in allografts without acute dysfunction. |
| Q36999202 | Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. |
| Q46874561 | Late developing C4d-positive humoral renal allograft rejection associated with withdrawal of mycophenolate mofetil |
| Q53894725 | Macrophages and T lymphocytes are the predominant cells in intimal arteritis of resected renal allografts undergoing acute rejection. |
| Q34360517 | Managing the highly sensitized transplant recipient and B cell tolerance |
| Q44260404 | Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. |
| Q38418186 | Monitoring B cell subsets and alloreactivity in kidney transplantation. |
| Q40591579 | Monotherapy with LF 15-0195, an analogue of 15-deoxyspergualin, significantly prolongs renal allograft survival in monkeys1 |
| Q43061583 | Mycophenolate mofetil: long-term outcomes in solid organ transplantation |
| Q36802609 | New treatments for acute humoral rejection of kidney allografts |
| Q47626280 | Non-ischemic left ventricular dysfunction after pediatric cardiac transplantation: treatment with plasmapheresis and OKT3. |
| Q35802158 | Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay |
| Q35210278 | Optimal cutoff point for immunoperoxidase detection of C4d in the renal allograft: results from a multicenter study |
| Q61813876 | Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR |
| Q44577632 | Outcome of simultaneous liver-kidney transplantation in highly sensitized, crossmatch-positive patients |
| Q37426021 | Pathologic findings in lung allografts with anti-HLA antibodies |
| Q35901211 | Peripheral deletion of mature alloreactive B cells induced by costimulation blockade |
| Q44608227 | Peritubular capillaritis in early renal allograft dysfunction is an indicator of acute rejection |
| Q44625727 | Plasmapheresis as rescue therapy in accelerated acute humoral rejection |
| Q35689912 | Plasmapheresis in C4d-positive acute humoral rejection following kidney transplantation: a review of 4 cases |
| Q43658900 | Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome. |
| Q46386615 | Potential value of high-dose mizoribine as rescue therapy for ongoing acute humoral rejection |
| Q43284783 | Predicting risk of acute rejection in patients with kidney transplants |
| Q33998148 | Pretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss. |
| Q46429084 | Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation |
| Q38338645 | Prolonged hypothermia causes primary nonfunction in preserved canine renal allografts due to humoral rejection |
| Q34823896 | Rejection and recipient age. |
| Q40198916 | Relevance of MICA antibodies in acute humoral rejection in renal transplant patients |
| Q36895544 | Renal transplantation in high-risk patients |
| Q44899030 | Rituximab as treatment for refractory kidney transplant rejection |
| Q37710374 | Sensitized renal transplant recipients: current protocols and future directions |
| Q34222399 | Significance of intragraft CD138+ lymphocytes and p-S6RP in pediatric kidney transplant biopsies |
| Q46843837 | Single dose of Rituximab plus plasmapheresis in an HIV patient with acute humoral kidney transplant rejection: a case report |
| Q44402537 | Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation |
| Q81813237 | Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection |
| Q80512157 | Soluble CD30 in patients with antibody-mediated rejection of the kidney allograft |
| Q95658177 | Successful Treatment of Antibody-Mediated Rejection by De Novo Donor Specific Antibody After Primary Renal Transplantation in a Recipient From a Cadaveric Donor: A Case Report |
| Q46216270 | Successful living related kidney transplantation across an anti-donor HLA antibody |
| Q40321824 | Successful rescue of refractory acute antibody-mediated renal allograft rejection with splenectomy--a case report |
| Q40958100 | Successful treatment of severe acute antibody-mediated rejection of renal allografts with bortezomib--a report of two pediatric cases |
| Q42598786 | Summary of FDA antibody-mediated rejection workshop |
| Q36984472 | The classical complement pathway in transplantation: unanticipated protective effects of C1q and role in inductive antibody therapy |
| Q52962136 | The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss. |
| Q39254100 | The effect of histopathologic and clinical features on allograft survival in renal transplant patients with antibody-mediated rejection |
| Q36570565 | The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation |
| Q43241187 | The prevalence of C4d-positive renal allografts in 134 consecutive biopsies in Thai patients |
| Q54116671 | The prognostic values of caveolin-1 immunoreactivity in peritubular capillaries in patients with kidney transplantation. |
| Q35583534 | The role of B cells and alloantibody in the host response to human organ allografts |
| Q79882539 | The role of angiotensin II type 1 receptor-activating antibodies in renal allograft vascular rejection |
| Q37992871 | The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection |
| Q37176570 | The spectrum of antibody-mediated renal allograft injury: implications for treatment |
| Q82064319 | The strength of donor-specific antibody is a more reliable predictor of antibody-mediated rejection than flow cytometry crossmatch analysis in desensitized kidney recipients |
| Q35199884 | The use of apheresis in immune renal disorders |
| Q30454250 | Therapeutic apheresis before and after kidney transplantation |
| Q42849688 | Treatment of Acute Antibody-Mediated Rejection: A Single-Center Experience |
| Q80252616 | Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil |
| Q73810381 | Use of C4d as a diagnostic adjunct in lung allograft biopsies |
| Q82564740 | [Antibody-mediated acute rejection] |
Search more.